Literature DB >> 25113330

[Therapy of prurigo nodularis].

C Zeidler1, S Ständer.   

Abstract

Treatment of prurigo nodularis is a challenge. No specific therapies are approved and data from clinical trials are rare. Based on our experience, case series, randomized controlled trials as well as the S2k guideline on chronic pruritus, we provide general principles and specific recommendations in this review.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25113330     DOI: 10.1007/s00105-014-2757-8

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   1.198


  28 in total

1.  Brachioradial pruritus: response to treatment with gabapentin.

Authors:  S M Winhoven; I H Coulson; W W Bottomley
Journal:  Br J Dermatol       Date:  2004-04       Impact factor: 9.302

2.  Evaluation of the antipruritic effects of topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized, hydrocortisone-controlled, double-blind phase II trial.

Authors:  Dorothee Siepmann; Tobias Lotts; Christine Blome; Matthias Braeutigam; Ngoc Quan Phan; Trude Butterfass-Bahloul; Matthias Augustin; Thomas A Luger; Sonja Ständer
Journal:  Dermatology       Date:  2013-11-23       Impact factor: 5.366

Review 3.  Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review.

Authors:  Ngoc Quan Phan; Tobias Lotts; Attila Antal; Jeffrey D Bernhard; Sonja Ständer
Journal:  Acta Derm Venereol       Date:  2012-09       Impact factor: 4.437

4.  Treatment of prurigo nodularis with pregabalin.

Authors:  M Mazza; G Guerriero; G Marano; L Janiri; P Bria; S Mazza
Journal:  J Clin Pharm Ther       Date:  2012-09-26       Impact factor: 2.512

5.  UVB 308-nm excimer light and bath PUVA: combination therapy is very effective in the treatment of prurigo nodularis.

Authors:  S Hammes; J Hermann; S Roos; H M Ockenfels
Journal:  J Eur Acad Dermatol Venereol       Date:  2010-10-15       Impact factor: 6.166

6.  Mirtazapine for pruritus.

Authors:  Mellar P Davis; Jan L Frandsen; Declan Walsh; Steven Andresen; Sandy Taylor
Journal:  J Pain Symptom Manage       Date:  2003-03       Impact factor: 3.612

7.  Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy.

Authors:  Sonja Ständer; Dorothee Siepmann; Ilka Herrgott; Cord Sunderkötter; Thomas A Luger
Journal:  PLoS One       Date:  2010-06-04       Impact factor: 3.240

Review 8.  ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis.

Authors:  U Darsow; A Wollenberg; D Simon; A Taïeb; T Werfel; A Oranje; C Gelmetti; A Svensson; M Deleuran; A-M Calza; F Giusti; J Lübbe; S Seidenari; J Ring
Journal:  J Eur Acad Dermatol Venereol       Date:  2009-08-31       Impact factor: 6.166

9.  Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study.

Authors:  Sonja Ständer; Barbara Böckenholt; Funda Schürmeyer-Horst; Carsten Weishaupt; Gereon Heuft; Thomas A Luger; Gudrun Schneider
Journal:  Acta Derm Venereol       Date:  2009       Impact factor: 4.437

10.  Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures.

Authors:  Sonja Ständer; Corinna Moormann; Mark Schumacher; Jörg Buddenkotte; Metin Artuc; Victoria Shpacovitch; Thomas Brzoska; Undine Lippert; Beate M Henz; Thomas A Luger; Dieter Metze; Martin Steinhoff
Journal:  Exp Dermatol       Date:  2004-03       Impact factor: 3.960

View more
  2 in total

Review 1.  [New treatment options for chronic pruritus].

Authors:  C Zeidler; B Pfleiderer; S Ständer
Journal:  Hautarzt       Date:  2016-08       Impact factor: 0.751

Review 2.  Hepatitis C virus-associated pruritus: Etiopathogenesis and therapeutic strategies.

Authors:  Youssef Alhmada; Denis Selimovic; Fadi Murad; Sarah-Lilly Hassan; Youssef Haikel; Mossaad Megahed; Matthias Hannig; Mohamed Hassan
Journal:  World J Gastroenterol       Date:  2017-02-07       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.